Extent and predictors of guideline-directed medical therapy optimization during cardiac rehabilitation in patients with heart failure

心力衰竭患者心脏康复期间指南指导的药物治疗优化程度及预测因素

阅读:1

Abstract

BACKGROUND: Cardiac rehabilitation (CR) may offer a structured framework for guideline-directed medical therapy (GDMT) optimization, but its real-world impact is uncertain. We aimed to quantify GDMT optimization and identify its clinical predictors during CR. METHODS: This retrospective single-centre study included patients hospitalized for acute HF with reduced (HFrEF) or mildly reduced (HFmrEF) ejection fraction who subsequently underwent first inpatient or ambulatory CR at Nancy University Hospital (2021-2024). Changes in GDMT optimization were evaluated using the HF prescription and the KCMO scores and expressed as adjusted standardized differences (ASD). Multivariable linear regression identified independent predictors of optimization. RESULTS: Among the 106 patients included (84 % HFrEF, mean age 59 years; 75 % male), baseline GDMT use was high, but doses were suboptimal. During CR, significant uptitration occurred across all major drug classes, including angiotensin receptor-neprilysin inhibitors (ASD: +22 %), beta-blockers (ASD: +21 %), mineralocorticoid receptor antagonists (ASD: +43 %), and sodium-glucose cotransporter 2 inhibitors (ASD: +45 %) (all p < 0.001). Overall GDMT optimization improved significantly, as evidenced by increases in both the KCMO (ASD: +39.9) and HF prescription (ASD: +1.27) scores (both p < 0.001), with consistent effects across inpatient and ambulatory settings. In multivariable analysis, higher loop-diuretic dose and prior treatment by HF specialists were associated with less optimization, whereas hypertension predicted greater intensification. CONCLUSIONS: Cardiac rehabilitation after HF hospitalization promoted substantial GDMT optimization, especially in hypertensive patients. Higher loop-diuretic dose at admission predicted less optimization, suggesting that minimizing diuretic doses may ease GDMT titration.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。